A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma

Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Qiuyun, Pan, Wentao, Zhou, Suna, Wang, Guangfeng, Yi, Hanjie, Zhang, Lin, Yan, Xianglei, Yuan, Luping, Liu, Zhenyi, Wang, Jing, Chen, Haibo, Qiu, MiaoZhen, Yang, DaJun, Sun, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851508/
https://www.ncbi.nlm.nih.gov/pubmed/32093809
http://dx.doi.org/10.3727/096504020X15825405463920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851508/
https://www.ncbi.nlm.nih.gov/pubmed/32093809
http://dx.doi.org/10.3727/096504020X15825405463920

Ejemplares similares